SCHEMBL18835230

SCHEMBL18835230

COc1ccc(-c2nc3c(n2Cc2ccc(F)cc2)C(=O)N(CCCO)C(O)N3C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 10/20 0.41
▸ SMN1; SMN2 Q16637 5/20 0.41
▸ HTT P42858 3/20 0.41
▸ LMNA P02545 3/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ CNR2 P34972 2/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ RGS4 P49798 1/20 0.40
▸ RGS8 P57771 1/20 0.40
▸ CYP1A2 P05177 5/20 0.40
▸ USP2 O75604 5/20 0.40
▸ CASP1 P29466 4/20 0.40
▸ CYP3A4 P08684 4/20 0.40
▸ HSD17B10 Q99714 3/20 0.40
▸ FAAH O00519 1/20 0.39
▸ CNR1 P21554 1/20 0.39
▸ ABHD6 Q9BV23 1/20 0.39
▸ P2RX3 P56373 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22105398 0.91 MEN1 (0.50) ALDH1A1SMN1; SMN2HTTLMNAKDM4E
SCHEMBL19505584 0.91 P2RX7 (0.39) ALDH1A1HTTMEN1KMT2ARGS4
SCHEMBL20432432 0.85 PDE5A (0.37) ALDH1A1RGS4RGS8CYP1A2USP2
SCHEMBL21316344 0.83 P2RX3 (0.40) ALDH1A1SMN1; SMN2HTTKDM4EMEN1
SCHEMBL20432022 0.82 TRPC4 (0.42) P2RX3
SCHEMBL18834253 0.82 ADORA3 (0.46) ALDH1A1SMN1; SMN2HTTLMNAMEN1
SCHEMBL20432069 0.81 TRPC5 (0.36) ALDH1A1LMNAKDM4ECNR2KMT2A
SCHEMBL21499680 0.81 P2RX3 (0.39) ALDH1A1SMN1; SMN2MEN1KMT2ACYP1A2
SCHEMBL19375398 0.81 P2RX3 (0.38) ALDH1A1SMN1; SMN2RGS4RGS8CYP1A2
SCHEMBL19375051 0.81 MDM2 (0.38) LMNACNR2L3MBTL1RGS4RGS8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11198696-B2 Substituted xanthines as inhibitors of transient receptor potential cation channel subfamily c, member 5 activity BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-12-14 — — US disclosed
US-20200190093-A1 SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2020-06-18 — — US disclosed
EP-2970303-B9 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES INC (US) 2017-09-20 — — EP disclosed
EP-2970303-B1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES INC (US) 2017-05-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200190093-A1 SUBSTITUTED XANTHINE DERIVATIVES TRPC5, TRPC4, TRPM5 ALDH1A1 869/4885SMN1; SMN2 1577/4885HTT 1317/4885
US-11198696-B2 Substituted xanthines as inhibitors of transient receptor potential cation channel subfamily c, member 5 activity TRPC5, TRPM5, TRPC4 ALDH1A1 1568/4885SMN1; SMN2 3424/4885HTT 2837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback